

ALLIED MINDS



H1 2018 Results

27 September 2018

Disclaimer

The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by **Allied Minds plc** (the "Company"). The information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below.

THIS PRESENTATION IS NOT A PROSPECTUS. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of the Company, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract whatsoever relating to any securities.

The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. To the extent permitted by law or regulation, no undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisors, or any other person, as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation. Save in the case of fraud, no responsibility or liability is accepted by any such person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, the Presentation. In addition, no duty of care or otherwise is owed by any such person to recipients of the Presentation or any other person in relation to the Presentation.


















Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future. The Presentation includes certain statements, estimates, opinions and projections provided by the Company in relation to strategies, plans, intentions, expectations, objectives and anticipated future performance of the Company and its subsidiaries. By their nature, such statements, estimates, opinions and projections involve risk and uncertainty since they are based on various assumptions made by the Company concerning anticipated results which may or may not prove to be correct and because they may relate to events and depend on circumstances that may or may not occur in the future and may be beyond the Company's ability to control or predict. No representations or warranties of any kind are made by any person as to the accuracy of such statements, estimates, opinions or projections, or that any of the events expressed or implied in any such statements, estimates or projections will actually occur. The Company is not under any obligation, and expressly disclaims any intention, to update or revise any such statements, estimates, opinions or projections following the date of this Presentation. No statement in the Presentation is intended as a profit forecast or a profit estimate.

Certain industry and market data contained in this Presentation has come from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice.

H1 strategic actions

Strategic action	Delivered
1. Strategic validation - syndication	<ul style="list-style-type: none">Boeing / BridgeSatRaytheon / HawkEye³⁶⁰STT pending with strategic leads
2. Enhanced leadership, governance and accountability	<ul style="list-style-type: none">Spin Transfer: John Kispert, ChairmanSciFluor: Bob Dempsey, DirectorPrecision Biopsy: Adam Savakus, COOLuxCath: Terry Ransbury, CTO; industry leaders join board; differentiated SABSignature Medical: differentiated SABHawkEye³⁶⁰ : Expands Advisory BoardBridgeSat: Boeing appointee, joins Craig Cooning, Director
3. Thematic investing	<ul style="list-style-type: none">Enhanced focus, leveraging competitive advantagesConnectivity: QuayChain and TableUpSpace: Orbital SideKick

Portfolio targeting premium exit valuations

Company	Year formed ⁽¹⁾	ALM % ownership ⁽²⁾	Selected strategic investors	Addressable market
 BRIDGE SAT, INC.	2014	81%	 BOEING  SPACE ANGELS NETWORK	>\$1.5bn (LEO) + GEO + aviation
 federated wireless	2012	52%	 ARRIS  AMERICAN TOWER	\$ multi-billion
 HawkEye ³⁶⁰	2015	48%	 Raytheon  Sumitomo Corporation of Americas	MDA = \$2.4bn (1 st target market)
 Spin Transfer Technologies <small>An Allied Minds Company</small>	2008	49%	Pending	NVM + SRAM + (M)DRAM = >\$20bn
 Orbital Sidekick	2018	Subst. min.	 11:2 CAPITAL	\$4bn+: Oil & gas infrastructure monitoring
 TableUp	2018	Subst. min.	-	Restaurant supply chain
QuayChain	2018	72%	-	Industrial supply chain
PRECISION BIOPSY <small>AN ALLIED MINDS COMPANY</small>	2008	65%	-	>\$4bn (US and EU)
 SciFluor <small>LIFE SCIENCES</small>	2010	70%	-	>\$8bn (injectables for retinal diseases)
 LuxCath, LLC <small>An Allied Minds Company</small>	2012	99%	-	2m US Afib patients, rising to 15.9m by 2050
 SIGNATURE MEDICAL <small>An Allied Minds Company</small>	2016	88%	RIoT  BOSE <small>Better sound through research®</small>	\$5bn (cost of heart failure readmission in US)

(1) Year of Allied Minds' investment in the case of Orbital Sidekick and TableUp

(2) Issued and outstanding share capital

H1 2018 milestones delivered

- Spin Polarizer demonstrated 40-70% efficiency gains
- Endurance Engine shown to increase endurance by up to 6 orders of magnitude, in line with DRAM
- Syndication of \$22.8m bridge
- Commercial agreements and strategic led Series B nearing completion

2018 operating objectives

- Demonstrate Spin Polarizer and Endurance Engine benefits
- Sign 2+ customer/partner agreements

Context / longer term objectives:

- NVM, SRAM, MDRAM and DRAM (>\$20 billion markets)

H1 2018 milestones delivered

- Application to FCC under Initial Commercial Deployment – 15 end-user partners across 16k sites nationwide
- ESC roll out to complete in Q1 19
- CPIs training program
- Contracts: Verizon, Telrad, Blinq

2018 operating objectives

- FCC certification
- Support multiple customer launches and realise commercial revenue
- Build out national ESC network

Context / longer term objectives:

- Federated Wireless leads the shared spectrum industry
- 5.4m access point market by 2022
- High margin SaaS model

H1 2018 milestones delivered

- \$14.9m Series A-3 round led by Raytheon and including Sumitomo - to accelerate first commercial cluster
- Pathfinder scheduled launch Q4 2018
- SEAKER (MDA) product in Beta testing
- Backlog build

2018 operating objectives

- Successfully launch pathfinder
- Launch Maritime Domain Awareness products and realise commercial revenue

Context / longer term objectives:

- Commercial revenue will build with clusters
- Expected to operate with x10 clusters at full capacity

H1 2018 milestones delivered

- \$10m series B - Boeing
- Boeing partnership
- NOC operational
- First ground station operational – Sierra
- Backlog
- 6 patent filings

2018 operating objectives

- Complete first ground station
- Demonstrate end-to-end service with pathfinder customer
- Sign 2+ customer agreements and build backlog

Context / longer term objectives:

- Only company building an optical ground network
- 10 ground stations envisaged for full capacity
- Target markets expanded to include GEO and aviation in addition to LEO

H1 2018 milestones delivered

- Bob Dempsey appointed to Board
- SF0166 tox study commenced

2018 operating objectives

- Initiate at least one Phase II trial for SF0166
- Complete in-life IND enabling study for one new asset

Context / longer term objectives:

- Existing injectable drugs for DME / Wet-AMD have aggregate sales >\$8 billion

H1 2018 milestones delivered

- Cohort B roll-in
- Prompted further work on data and algorithm
- Delay to commencement of full Cohort B study – 2019
- Knock-on delays in 3D mapping



2018 operating objectives

- Gain CE Mark
- Complete Cohort B trial for ClariCore
- FiM studies for 3D mapping

Context / longer term objectives:

- Cohort B to unlock FDA approval
- 3D mapping product – gateway to focal therapy

Earlier stage portfolio

Subsidiary	Description / H1 2018 milestones delivered	2018 milestones
	<p>Developing catheter ablation initially focused on atrial fibrillation using real-time tissue and lesion visualisation technology</p> <ul style="list-style-type: none"> • Progressed development of proprietary catheter • Formed Scientific Advisory Board 	<ul style="list-style-type: none"> • Prototype integrated proprietary catheter and optical device to be produced and tested • Patient trials to follow (timing TBD)
	<p>Developing wearable cardiac signature technology enabling diagnosis and monitoring of heart failure during hospital therapy and post discharge</p> <ul style="list-style-type: none"> • Progressed development of AcoustiCare prototype • Formed Scientific Advisory Board 	<ul style="list-style-type: none"> • Collect acoustic data to train and validate algorithm • Build IP position

Key Financial Metrics

OAV

\$350.1M – Total
\$322.6M – Top 6

11.5% reduction
overall
Top 6 represent
92% of OAV

Cash

\$132.2M -
Group
\$66.0M - Parent

Parent holds
cash to fund
operations into
2020

Portfolio Investment

\$22.6M – Total
\$10.3M – From
co-investors

3 subsidiaries
raised cash
during 2018 to
date

In conclusion: H1 highlights

- High grade appointments across the portfolio
- Technology portfolio, financed by and partnering with Tier 1 strategics: validation and substantial commercial advantages
 - Boeing / BridgeSat: investment and contribution of resources
 - Raytheon / HawkEye³⁶⁰: investment and broader partnership
 - Spin Transfer – pending agreements with at least two industry leaders
- Confidence in near term (2019) commercialisation of Federated Wireless, Spin Transfer and HawkEye³⁶⁰
- 3 new investments – space and connectivity

ALLIED MINDS



Appendix

Selected financial highlights

\$ millions

For the 6 months ended:	30 June 2017	30 June 2018
Revenue	2.0	2.1
Net profit	(58.3)	4.2
Investment in portfolio	24.0	23.8
Of which Allied Minds	22.4	12.3
Of which co-investors	1.6	11.5
As of:	31 December 2017	30 June 2018
Cash and deposits – group	169.1	132.2
Cash and deposits – parent	84.2	66.0
As of:	31 December 2017	30 June 2018
OAV	395.6	350.1
OAV – top 6 companies	375.3	322.6



ALLIED MINDS

Thank you